DDRE-23. THE COMBINATION PARP INHIBITOR OLAPARIB WITH TEMOZOLOMIDE IN AN EXPERIMENTAL GLIOBLASTOMA MODEL

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2020-11, Vol.22 (Supplement_2), p.ii66-ii66
• Main Authors: Hwang, Kihwan, Go, Kyeong-O, Kim, Sang Ho, Lee, Hyunwoo, Han, Jung Ho, Kim, Chae-Yong
• Format: Article
• Language: English
• Subjects: Drug Discovery, Drug Resistance
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/noaa215.268

Poly (ADP-ribose) polymerase (PARP) inhibition could enhance the efficacy of temozolomide and prolong survival in patients with glioblastoma. The aim of this study was to evaluate the combination of the PARP inhibitor olaparib with temozolomide in the treatment of glioblastoma by evaluating in vitro and in vivo antitumor effects in an experimental glioblastoma model. The authors investigated antitumor effects of olaparib on temozolomide-induced cytotoxicity on O6-methylguanine methyltransferase (MGMT) promotor methylated (U87MG, U251MG) and MGMT promotor unmethylated (T98G) glioblastoma cell lines using in vitro cell viability and apoptosis assay. We found that the combination of olaparib with temozolomide enhanced temozolomide-induced cytotoxicity in all glioblastoma cell lines regardless of the status of MGMT promotor methylation. For in vivo studies, nude mice bearing orthotopically xenografted glioblastoma cell lines (U87MG) were randomized to four experimental groups: (i) untreated, (ii) temozolomide alone, (iii) olaprib alone and, (iv) olaparib+temozolomide. Mice were treated daily for 4 weeks and monitored for tumor growth, and survival. However, the addition of olaparib had no impact on the efficacy of temozolomide. The combination of PARP inhibitor olaparib with temozolomide could be an effective therapeutic approach for treatment of glioblastoma regardless of MGMT promotor methylation status, although the efficacy still should be evaluated by in vivo and clinical studies.